Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

This pilot phase I/II trial studies the best dose of erlotinib hydrochloride and to see how
well it works in preventing liver cancer in patients with scarring (cirrhosis) of the liver.
Erlotinib hydrochloride may help to inhibit the development of fibrous tissue and prevent
liver cancer from forming in patients with cirrhosis of the liver.


Erlotinib, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment


Cirrhosis, Hepatocellular Carcinoma


Kenneth K Tanabe

See list of participating sites